Patterns of bone metastases in newly diagnosed colorectal cancer: a real-world analysis in the SEER database

Guo, Xu; Zhang, Chao; Ma, Wenjuan; Tian, Fei; Xu, Ge‐Liang; Han, Xiuxin; Sun, Peng; Baklaushev, V. P.; Bryukhovetskiy, Andrey; Wang, Guowen; Ma, Yonggang; Wang, Xin

doi:10.1007/s00384-018-3213-5

Cited by 26 publications

(21 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, surgery was not an independent survival factor of the patients with malignant GCTB in the present study. The effect of surgery on the survival of patients with malignant GCTB was different from its effect in other malignant cancers, such as colorectal cancer [27] and ovarian cancer [28]. This difference may be caused by the significantly higher survival in giant cell tumours than in other malignant cancers.…”

Section: Discussionmentioning

confidence: 87%

Survival and prognostic factor analyses in malignant giant cell tumour of bone

Zhang¹,

Wang

Lin³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The characteristics and survival of patients with malignant giant cell tumour of bone (GCTB) have not been investigated thoroughly due to the rarity of the disease. We evaluated these factors in a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database.Methods: Data from patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival (OS) was calculated by Kaplan–Meier analysis, and intergroup differences were tested by the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were conducted to identify the independent survival factors.Results: A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. A potential non-linear J-shaped dose–response relationship between the age or diagnosis year and survival were found. Multivariate Cox regression showed poor survival in patients with age from 35 to 60 years (hazard ratio (HR) =9.99, 95% CI: 1.34-74.80, P=0.025), age older than 60 years (HR=62.03, 95% CI: 7.94-484.38, P<0.001), with stage T2 disease (HR=4.85, 95% CI: 1.52-15.47, P=0.008), with stage T3 disease (HR=6.09, 95% CI: 1.03-36.23, P=0.047), and with distant tumours (HR=2.76, 95% CI: 1.14-6.65, P=0.024), and extraskeletal sites (HR=3.33, 95% CI: 1.02-10.85, P=0.046).Conclusions: This large population-based series described the clinical characteristics of malignant GCTB. Patients with stage T2/3disease, distant disease and extra-skeletal sites had more odds to be with worse survival. The elder age than 34 years had a gradually increased risk for survival.

show abstract

Section: Discussionmentioning

confidence: 87%

Survival and prognostic factor analyses in malignant giant cell tumour of bone

Zhang¹,

Wang

Lin³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similarly, surgery was not an independent survival factor of the patients with malignant GCTB in the present study. The effect of surgery on the survival of patients with malignant GCTB was different from its effect in other malignant cancers, such as colorectal cancer [27] and ovarian cancer [28]. This difference may be caused by the signi cantly higher survival in giant cell tumours than in other malignant cancers.…”

Section: Discussionmentioning

confidence: 90%

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Zhang¹,

Wang²,

Lin³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The characteristics and survival of patients with malignant giant cell tumour of bone (GCTB) have not been investigated thoroughly due to the rarity of the disease. We evaluated these factors in a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database.Methods: Data from patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival was calculated by Kaplan–Meier analysis, and intergroup differences were tested by the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were conducted to identify the independent survival factors.Results: A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. A potential non-linear J-shaped dose–response relationship between the age or diagnosis year and survival were found. Multivariate Cox regression showed poor survival in patients with age from 35 to 60 years (HR=9.99, 95% CI: 1.34-74.80, P=0.025), age older than 60 years (HR=62.03, 95% CI: 7.94-484.38, P<0.001), with stage T2 disease (HR=4.85, 95% CI: 1.52-15.47, P=0.008), with stage T3 disease (HR=6.09, 95% CI: 1.03-36.23, P=0.047), and with distant tumours (HR=2.76, 95% CI: 1.14-6.65, P=0.024), and extraskeletal sites (HR=3.33, 95% CI: 1.02-10.85, P=0.046).Conclusions: This large population-based series described the clinical characteristics of malignant GCTB. Patients with stage T2/3 disease, distant disease and extra-skeletal sites had more odds to be with worse survival. The elder age than 34 years had a gradually increased risk for survival.

show abstract

“…Similarly, the surgery was not an independent survival factor of the patients with malignant GCTB in the present study. The effect of surgery on the survival of malignant GCTB was different from other malignant cancers such as colorectal cancer [26] and ovarian cancer [27]. The difference may be caused by significantly higher survival in the giant cell tumor than other malignant cancers.…”

Section: Discussionmentioning

confidence: 99%

Survival and prognostic factors analyses in malignant giant cell tumor of bone

Zhang¹,

Wang

Lin³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The characteristics and survival in patients with malignant giant tumor cancer of bone (GCTB) have not been investigated thoroughly due to the limited population. We evaluated the issues based on a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. Methods: Patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival (OS) was calculated by Kaplan–Meier analysis and the inter-group difference was tested by log-rank test. Univariate and multivariate Cox proportional hazard regression were conducted to identify the independent survival factors. Results: A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. In the univariate analysis, age older than 34 years, grade IV, T2/3 stage, M1, distant and surgery of the primary site were independent factors for worse survival. Multivariate Cox regression showed the poor survival in patients with age older than 34 years (hazard ratio (HR) =3.65, 95% CI: 2.04-6.56, P <0.001), T2 stage (HR=4.85, 95% CI: 1.52-15.47, P =0.008), and distant tumor (HR=2.93, 95% CI: 1.24-6.88, P =0.014), and the extra-skeletal sites (HR=8.84, 95% CI: 2.89-27.07, P <0.001), respectively. Conclusions: This large population-based series described the clinical characteristics of the malignant GCTB. Age >34 years, T2, distant stage and extra-skeletal sites were associated with worse survival in the patients with malignant GCTB.

show abstract

Patterns of bone metastases in newly diagnosed colorectal cancer: a real-world analysis in the SEER database

Cited by 26 publications

References 17 publications

Survival and prognostic factor analyses in malignant giant cell tumour of bone

Survival and prognostic factor analyses in malignant giant cell tumour of bone

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Survival and prognostic factors analyses in malignant giant cell tumor of bone

Contact Info

Product

Resources

About